Loading...

Vallon Pharmaceuticals, Inc.

VLON•NASDAQ
Healthcare
Biotechnology
$0.40
$-0.06(-13.04%)

Vallon Pharmaceuticals, Inc. (VLON) Stock Overview

Explore Vallon Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for VLONStats details for VLON are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for VLONAnalyst Recommendations details for VLON are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

CEO

Mr. David C. Baker

Employees

2

Headquarters

Two Logan Square, Philadelphia, PA

Founded

2021

Frequently Asked Questions

;